Neratinib plus Kadcyla to treat leftover HER2 breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This trial studies whether adding neratinib to Kadcyla (T-DM1) can help eliminate “molecular residual disease,” meaning tiny traces of cancer left after surgery and standard HER2 treatment. It’s for adults with HER2-positive breast cancer who still test positive after a short course of Kadcyla, with no signs of cancer returning or spreading on scans.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 18 or older with HER2-positive breast cancer that was removed by surgery (stage I–III).
- After earlier chemotherapy with trastuzumab (and possibly pertuzumab), you still had invasive cancer after surgery.
- You are currently taking Kadcyla (T-DM1), and a sensitive blood test (Inivata RaDaR) is positive for molecular residual disease after 2–6 cycles.
- You have no signs of cancer returning or spreading on scans and exam (not metastatic).
- You have not taken neratinib or any other HER2 “kinase inhibitor” drug before.
- Your heart and organs are healthy enough for treatment, and you can use highly effective birth control if needed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether neratinib plus capecitabine can slow or shrink breast cancer that has spread to the brain. It is for people whose cancer shows an “overactive HER2 signal” on a specific tumor test, even though their cancer is labeled HER2-negative.
This trial tests whether taking neratinib after completing a year of standard treatment can help prevent breast cancer from coming back in women who had a complete response to initial therapy but still have high-risk features.
This trial studies whether adding neratinib to standard trastuzumab treatment after neoadjuvant (before-surgery) therapy lowers the risk of breast cancer coming back. It is for people whose breast cancer is hormone-receptor positive and HER2 positive, with residual cancer found after neoadjuvant treatment.
This trial is testing whether adding neratinib after standard treatment helps prevent HER2-positive early breast cancer from coming back. It is open only to patients treated at Peking University People's Hospital.
This trial is for people with HER2-positive breast cancer who still had cancer after initial chemotherapy. It tests the safety and effectiveness of a drug called T-DM1 (Kadcyla) given after surgery to reduce the chance of the cancer coming back.
This study tests whether a pre-surgery treatment plan that adds neratinib to hormone therapy and trastuzumab can shrink HER2-positive, ER-positive breast cancer before surgery. It may help patients by improving how much cancer is eliminated at the time of surgery.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.